טוען...

Effect of sirolimus on immune reconstitution following myeloablative allogeneic stemcell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402)

INTRODUCTION: Although allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for hematologic neoplasms, one of its limiting toxicities continues to be graft versus host disease, both acute and chronic (aGVHD, cGVHD). Sirolimus is a mammalian target of rapamycin (mTOR)...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	Biol Blood Marrow Transplant
Main Authors:	Gooptu, Mahasweta, Kim, Haesook T., Howard, Alan, Choi, Sung W., Soiffer, Robert J., Antin, Joseph H., Ritz, Jerome, Cutler, Corey S.
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	2019
נושאים:	Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7304072/ https://ncbi.nlm.nih.gov/pubmed/31271885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.06.029
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Effect of sirolimus on immune reconstitution following myeloablative allogeneic stemcell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402)

פריטים דומים